International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 633-640 www.ijprajournal.com ISSN: 2456-4494

"The Potential of Botanical Resources in Drug Discovery: A Review of Plant-Derived Therapeutic Agents"

Chhaya Choudhary[1*], VishvnathPratap Gupta[2], Bhupendra Tiwari[3], Gopesh Gunjan[4]

[1]*Student- Globus College of Pharmacy, located in Bangrasia, Bhopal(M.P)*
[2]*Professor& Principal- Globus College of Pharmacy, located in Bangrasia,Bhopal (M.P)*
[3]*Assistant Professor- Globus College of Pharmacy, located in Bangrasia, Bhopal, (M.P)*
[4]*Assistant Professor- Globus College of Pharmacy, located in Bangrasia,Bhopal(M.P)*

Date of Submission: 15-09-2025 Date of Acceptance: 25-09-2025

ABSTRACT
Plants have long served as a foundation for healthcare, from traditional remedies to modern pharmaceutical innovations. They produce an extraordinary array of secondary metabolites, including alkaloids, flavonoids, terpenoids, glycosides, phenolics, and tannins, many of which possess therapeutic potential. Several plant-derived drugs such as morphine, quinine, artemisinin, paclitaxel, and digoxin remain indispensable in clinical medicine today. Despite advances in synthetic chemistry and biotechnology, plants continue to play a central role in drug discovery due to their structural diversity and biological activities. This review highlights the historical contributions of plants to pharmacology, the diversity of phytochemicals, their therapeutic applications in modern medicine, the challenges associated with their development, and future prospects. By bridging ethnopharmacological knowledge with contemporary scientific tools, botanical resources represent a promising frontier for the discovery of novel therapeutic agents.

Keywords: botanical resources, drug discovery, phytochemicals, plant-derived drugs, natural products, therapeutic agent

I. INTRODUCTION

Plants have been integral to human health for millennia, serving as the earliest source of medicine across cultures. Ancient systems such as Ayurveda, Traditional Chinese Medicine, and African ethnomedicine relied heavily on botanicals to manage diseases. Medicinal plants have been an integral part of healthcare for centuries and continue to provide a vital source of novel bioactive compounds**(Dar et al., 2023).** The World Health Organization (WHO) estimates that approximately 80% of the global population relies on plant-based medicines for primary healthcare needs. With growing antimicrobial resistance and the limitations of synthetic drugs, botanical resources offer a valuable alternative for the discovery of new therapeutic agents. The structural diversity and complexity of plant-derived compounds make them attractive for drug development in areas such as oncology, infectious diseases, cardiovascular disorders, and neurological conditions**(Chaachouay and Zidane 2024).**

Development of new drug is a complex, time-consuming, and expensive process. The time taken from discovery of a new drug to its reaching the clinic is approximately 12 years, involving more than 1 billion US$ of investments in today's context. Essentially, the new drug discovery involves the identification of new chemical entities (NCEs), having the required characteristic of drug ability and medicinal chemistry. These NCEs can be sourced either through chemical synthesis or through isolation from natural products**(Branch and Agranat 2014).** Initial success stories in new drug discovery came from medicinal chemistry inventions, which led to the need of development of higher number of chemical libraries through combinatorial chemistry. This approach, however, was proven to be less effective in terms of overall success rate. The second source of NCEs for potential use as drug molecules has been the natural products**(Newman and Cragg 2020).** Before the advent of high throughput screening and the post genomic era, more than 80% of drug substances were purely natural products or were inspired by the molecules derived from natural sources (including semi-synthetic analogs). An analysis into the sources of new drugs from 1981 to 2007 reveals that almost half of the drugs approved since 1994 were based on natural products. During the years 2005–2007, 13 natural product related drugs were approved **(Harvey et al., 2015).** There are various examples of development of new drugs from the plant sources. Morphine was isolated from

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 633-640 www.ijprajournal.com ISSN: 2456-4494

opium produced from cut seed pods of the poppy plant (Papaversomniferum) approximately 200 years ago. Pharmaceutical research expanded after the second world war to include massive screening of microorganisms for new antibiotics, inspired by the discovery of penicillin. Few drugs developed from natural sources have undoubtedly revolutionized medicine, like antibiotics (e.g. penicillin, tetracycline, erythromycin), antiparasitics (e.g. avermectin), antimalarials (e.g. quinine, artemisinin), lipid control agents (e.g. lovastatin and analogs), immunosuppressants for organ transplants (e.g. cyclosporine, rapamycins), and anticancer drugs (e.g. paclitaxel, irinotecan)**(Durand et al., 2019).**

II. HISTORICAL CONTRIBUTIONS OF PLANTS TO DRUG DISCOVERY

Plants have made profound contributions to modern pharmacology by providing bioactive compounds that remain indispensable in clinical medicine. Many of the earliest drugs were directly derived from plants, and their success stories paved the way for integrating natural products into drug discovery pipelines **(Tran et al., 2020).**

Some landmark examples include:

2.1 Morphine

Morphine's primary historical contribution is marking the dawn of modern drug discovery by demonstrating that a pure, powerful, and reproducible active compound could be isolated from a plant, specifically the opium poppy (Papaversomniferum) by Friedrich Wilhelm Adam Sertürner in 1805**(Upton et al., 2016).** This breakthrough shifted medicinal understanding from crude plant extracts to the isolation and characterization of individual pharmacologically active substances, laying the foundation for the pharmaceutical industry and the development of other plant-derived medicines. The successful isolation of morphine set a precedent for other discoveries. This led to the isolation of other crucial plant-derived compounds, such as quinine (from the cinchona tree), digitoxin (from foxglove), and cocaine (from the coca plant) **(Kinghorn and Kennelly 2020).**

2.2 Quinine –

Quinine was historically crucial to drug discovery as the first effective chemotherapeutic for malaria, isolated from the bark of the Cinchona tree by Indigenous peoples in the Andes and brought to Europe in the 17th century **(Kayser, 2024).** Quinine derived from the bark of Cinchona officinalis, historically a frontline antimalarial drug. The isolation of pure quinine in 1820 enabled reliable dosing, establishing it as the first modern chemotherapy. The discovery also spurred the synthetic dye industry, which in turn led to Paul Ehrlich's work on small molecule drugs and selective toxicity, fundamental concepts in modern pharmacology **(Manaviet al., 2024).**

2.3 Reserpine

Reserpine's historical contribution to drug discovery lies in its derivation from the Indian medicinal plant Rauwolfiaserpentina, leading to the first effective psychiatric drugs and one of the earliest treatments for high blood pressure**(Singh, 2017).**Isolated in 1952, reserpine was a crucial component of the burgeoning field of psychopharmacology, demonstrating how naturally occurring compounds could be developed into modern medicines and sparking further research into plant-based natural products for drug discovery. Reserpine was one of the first drugs to effectively treat high blood pressure (hypertension), It was also used as an antipsychotic, particularly for schizophrenia, and helped usher in the field of psychopharmacology**(Weir, 2020).**

The success of reserpine highlighted the enormous potential of plants as a source of valuable pharmaceutical compounds, prompting further research into their medicinal properties. Reserpine's mechanism of action, which involves depleting biogenic amines (like dopamine and serotonin) from nerve endings, provided crucial insights into the role of these neurotransmitters in the brain and their connection to mental health conditions **(Ghallab and Elassal 2024).**

2.4 Artemisinin

The discovery of Artemisinin is a landmark example of historical contributions of plants to drug discovery, with the compound being isolated from the Artemisia annua plant (sweet wormwood) by Chinese scientists, led by YouyouTu, in 1972**(Schürrle, 2019).**The plant had a long history of use in Traditional Chinese Medicine for treating fevers and malaria. The identification of artemisinin, a sesquiterpene endoperoxide lactone, provided a novel, potent antimalarial drug with a distinct chemical structure, effectively combating chloroquine-resistant malaria and leading to the development

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 633-640 www.ijprajournal.com ISSN: 2456-4494

of artemisinin-based combination therapies (ACTs), which are now the WHO-recommended standard treatment for malaria worldwide**(Luisi, 2023).**Artemisinin proved highly effective against Plasmodium falciparum, the deadliest malaria parasite. The drug's unique chemical structure provided a solution to the growing problem of resistance to existing antimalarials like chloroquine. Artemisinin-based combination therapies (ACTs) became the standard treatment for malaria, recommended by the World Health Organization (WHO). Artemisia annua and its derivatives are now being explored for other potential uses, including in treating metabolic diseases, and for their anti-inflammatory and anti-tumor properties**(van der Pluijmet al., 2021).**

2.5 Paclitaxel (Taxol) –

Paclitaxel, an important anti-cancer drug, was discovered in the 1960s from the bark of the Pacific yew tree (Taxusbrevifolia) through the National Cancer Institute's (NCI) plant screening program, which sought naturally occurring compounds with anticancer activity. After isolation and extensive research over two decades, the drug was approved for breast and ovarian cancers, expanding treatment options and offering hope for patients**(Sarkar, 2023).**

The slow-growing nature of the Pacific yew tree created a significant shortage of the compound, impacting drug availability and clinical trials. Paclitaxel showed promise in preclinical trials, but the initial lack of a water-soluble formulation and the limited supply dampened enthusiasm. A water-insoluble formulation using polyethoxylated castor oil (a component of the final drug, also known as Cremophor EL) was developed, leading to the approved drug. After about two decades, paclitaxel was approved as a drug to treat several cancers, including breast and ovarian cancer, representing a significant advancement in cancer treatment **(Ejetaet al., 2024).**

2.6 Digoxin –

The plant foxglove (Digitalis lanata) is the historical source for the cardiac drug digoxin. Early uses of foxglove for heart conditions like dropsy (edema) date back to the 18th century, documented by English physician William Withering. The purified compound digoxin was later isolated from the plant's leaves in 1930 by Dr. Sydney Smith, leading to its widespread medical application and eventual FDA approval in 1954 for treating conditions like heart failure and atrial fibrillation **(Khandelwal et al., 2024).**

Digoxin, a cardiac glycoside employed in treating heart conditions, was initially isolated in 1930 by Dr. Sydney Smith from the foxglove plant Digitalis lanata. The isolation process entailed extracting the glycosides from the woolly foxglove, yielding digoxin as one of the resultant compounds. Subsequently, the purification of digoxin involved breaking down its glycosidic bonds within the body, forming digitoxin and sugars **(Khandelwal et al., 2024).**The historical significance of digoxin's discovery lies in its herbal origins rather than laboratory synthesis. In 1775, English physician William Withering discovered the therapeutic potential of the foxglove plant in treating conditions such as dropsy (edema). This breakthrough led to the widespread use of digitalis for medical purposes. Digoxin continues to be derived from the foxglove plant through a modern manufacturing process, which involves extracting digitalis from dried foxglove leaves to produce pure digoxin for pharmaceutical applications. The purification and extraction of digoxin from Digitalis lanata have facilitated its extensive utilization in managing various cardiac conditions over the past century**(WhayneJr, 2018).**

Table 1. Major Plant-Derived Drugs and Their Therapeutic Applications

Drug	Source plant	Class	Therapeutic use	Year of Discovery/Approval
Morphine	Papaversomniferum (Opium poppy)	Alkaloid	Analgesic (pain relief)	1806
Quinine	Cinchona officinalis (Cinchona bark)	Alkaloid	Antimalarial	1820s
Reserpine	Rauwolfiaserpentina (Indian snakeroot)	Alkaloid	Antihypertensive, antipsychotic	1950s
Digoxin	Digitalis purpurea (Foxglove)	Glycoside	Heart failure, arrhythmias	1785

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 633-640 www.ijprajournal.com ISSN: 2456-4494

Artemisinin	Artemisia annua (Sweet wormwood)	Sesquiterpene lactone	Antimalarial	1972
Paclitaxel (Taxol)	Taxusbrevifolia (Pacific yew)	Terpenoid	Anticancer (breast, ovarian, lung)	1992
Vincristine / Vinblastine	Catharanthusroseus (Madagascar periwinkle)	Alkaloid	Anticancer (leukemia, lymphoma)	1960s
Salicylic acid / Aspirin	Salix alba (Willow bark)	Phenolic derivative	Analgesic, antipyretic, cardioprotective	1899
Ephedrine	Ephedra sinica (Ma Huang)	Alkaloid	Bronchodilator, nasal decongestant	Early 20th century
Galantamine	Galanthusnivalis (Snowdrop)	Alkaloid	Alzheimer's disease	2001 (FDA approval)

III. PHYTOCHEMICALS AS DRUG LEADS

Plants produce a wide range of secondary metabolites with therapeutic potential.

3.1 Alkaloids: Alkaloids are a vital class of phytochemicals with diverse biological activities, making them valuable lead compounds for drug development in areas such as pain, cancer, metabolic disorders, and neurodegenerative diseases. Their chemical diversity, historical use in traditional medicine, and ability to target cellular pathways contribute to their importance as sources for new therapies, despite challenges with bioavailability and complexity. Examples include morphine for pain, vinblastine for cancer, and berberine for metabolic health. Certain alkaloids protect neuronal cells and can help mitigate neuroinflammation and oxidative stress in conditions like Alzheimer's disease **(Hussain et al., 2018).**

3.2 Flavonoids: Flavonoids are bioactive phytochemicals in plants with promising therapeutic properties, such as anticancer, antioxidant, and anti-inflammatory activities, making them valuable "drug leads". They are found in fruits, vegetables, tea, and wine and work by targeting various molecular pathways involved in diseases. While their potential is significant, clinical applications are limited by poor bioavailability and delivery challenges, which researchers are actively addressing through techniques like analog synthesis, precision medicine approaches, and advanced computational methods **(Chihomvuet al., 2024).**

3.3 Terpenoids: Terpenoids, the largest and most diverse group of phytochemicals, are actively studied as drug leads due to their broad range of biological activities, including anticancer, anti-inflammatory, antiviral, and antimalarial properties. They are classified by the number of isoprene units they contain and include famous drugs like the anticancer agent paclitaxel (Taxol) and the antimalarial artemisinin. Terpenoids also exhibit antioxidant, antibacterial, and immunomodulatory effects, making them promising candidates for treating metabolic diseases, neurodegenerative disorders, and combating drug resistance. While significant potential exists, challenges include understanding their bioavailability, reducing side effects, and developing effective formulation strategies**(Monyet al., 2022).**

3.4 Phenolics and Tannins: Phenolic compounds, including tannins, serve as valuable drug leads due to their diverse pharmacological properties like antioxidant, anti-inflammatory, and enzyme-inhibiting actions, which can be harnessed for treating various diseases. Modern research focuses on isolating and characterizing these phytochemicals, such as flavonoids and phenolic acids, to develop novel pharmaceutical agents from their potent bioactivity. The phenolic class is extensive, encompassing flavonoids, phenolic acids, and tannins. These diverse structures allow for varied interactions with biological targets, forming the basis for their therapeutic potential**(Ogbuaguet al., 2022).**

Phenolic compounds are abundant in plants, found in various organs and their extracts. Research involves extracting these compounds from

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 633-640 www.ijprajournal.com ISSN: 2456-4494

medicinal plants and screening for their biological and pharmacological activities to discover potential drug leads **(Alaraet al., 2021).**

3.5 Glycosides: Glycosides are phytochemicals that have shown great potential as drug leads due to their broad therapeutic applications, including treating heart conditions, diabetes, inflammation, and cancer. These plant-derived compounds consist of a sugar molecule linked to a non-sugar part, called an aglycone, and serve as vital components in drug discovery for various ailments**(Riaz et al., 2023).**

Glycosides demonstrate a wide range of therapeutic effects against numerous diseases, including cardiovascular issues, cancer, and diabetes. Being abundant in various medicinal plants, particularly in regions like India, they offer a sustainable and readily available source for drug development. In plants, glycosides play crucial roles in growth regulation, defense against pathogens and herbivores, and storing toxins. These inherent biological functions make them effective candidates for pharmaceutical applications. Compared to some synthetic drugs, bioactive compounds from plants, including glycosides, are often associated with fewer side effects, increasing their appeal in drug development **(Riaz et al., 2023).**

IV. THERAPEUTIC APPLICATIONS OF PLANT-DERIVED DRUGS

4.1 Antimicrobial Agents

The rise of infectious diseases and the alarming spread of antimicrobial resistance (AMR) have renewed global interest in plant-derived compounds as alternative or complementary antimicrobial therapies. Plants synthesize a diverse array of bioactive metabolites that serve as chemical defenses against pathogenic microbes in their natural environments. Many of these phytochemicals exhibit strong antibacterial, antifungal, antiviral, and antiparasitic properties, making them valuable candidates for drug discovery **(Tiwari et al., 2023).**

4.2 Anticancer Agents

Cancer remains one of the leading causes of morbidity and mortality worldwide, with millions of new cases diagnosed each year. Despite advances in targeted therapy and immunotherapy, conventional chemotherapy continues to play a central role in cancer management. Plant-derived compounds have significantly shaped the field of oncology by providing structurally unique molecules with potent anticancer activity. Many of these agents interfere with cell division, induce apoptosis, or inhibit angiogenesis, making them indispensable in clinical practice**(Bray et al., 2018).**

4.3 Cardiovascular and Metabolic Disorders

Cardiovascular and metabolic disorders, including hypertension, heart failure, diabetes mellitus, and hyperlipidemia, are among the leading causes of global morbidity and mortality. The search for effective therapeutic agents has consistently drawn upon plant-derived compounds, many of which remain central to contemporary treatment strategies. Phytochemicals such as alkaloids, glycosides, flavonoids, and terpenoids have demonstrated significant cardioprotective and metabolic regulatory properties, providing the foundation for both traditional and modern therapies**(Bozkurt et al., 2016).**

4.4 Neurological and Psychiatric Disorders

Reserpine and galantamine (Galanthus spp.) illustrate the potential of phytochemicals in treating neurological and psychiatric conditions, including Alzheimer's disease **(Ayaz et al., 2019).**

4.5 Antioxidant Activity

Antioxidants are substances that fight against free radicals in the cells, which otherwise highly contribute to developing heart disease, cancer, and other diseases **(Sharma, 2014).**The phytochemical investigation of Nelumbonucifera embryos revealed the antioxidant activity of its four main alkaloids, named neferine, isoliensinine, liensinine, and armepavine. Using the 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulfonic acid (ABTS) and 2,2,-diphenyl-1-picrylhydrazyl (DPPH) radical scavenging assays, the drug concentration eliciting 50% of the maximum simulation (SC_{50}) values for these compounds was identified as 14.65, 12.07, 18.25, and 29.03 μM for ABTS and 33.37, 25.26, 44.21, and 79.34 μM for DPPH, respectively **(Aryalet al., 2022).**

V. MODERN RELEVANCE OF BOTANICAL RESOURCES

The global burden of diseases such as antimicrobial resistance (AMR), cancer, cardiovascular disorders, diabetes, and

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 633-640 www.ijprajournal.com ISSN: 2456-4494

neurodegenerative diseases has increased the urgency for discovering novel therapeutic agents. Synthetic drug pipelines have struggled to keep pace with the rapid evolution of resistant pathogens, leading scientists to re-examine natural products as reservoirs of new lead molecules**(Daley and Cordell 2021).**

Botanical resources are particularly relevant because:

- They often contain compounds with multiple mechanisms of action, reducing the risk of resistance development.
- Many plant-derived molecules interact with biological targets that are not easily addressed by synthetic compounds.
- Traditional knowledge offers a starting point for identifying bioactive plants, reducing the time and cost associated with random screening approaches**(Pushpangadanet al., 2018).**

VI. CHALLENGES IN PLANT-BASED DRUG DISCOVERY

Despite their potential, several challenges hinder the large-scale integration of plant-derived compounds into modern therapeutics:

- **Phytochemical variability:** The concentration of active constituents can vary widely depending on geographical origin, soil type, climate, and harvesting methods.
- **Low yields:** Some plants produce active compounds in minute quantities, making large-scale extraction unsustainable.
- **Standardization issues:** Unlike synthetic drugs, herbal extracts often contain complex mixtures of compounds, making it difficult to ensure batch-to-batch consistency **(Shukla et al., 2023).**
- **Safety and toxicity concerns:** While considered "natural," not all plant compounds are safe; some exhibit toxic effects or interact negatively with other drugs.
- **Conservation concerns:** Overharvesting of medicinal plants, especially rare and endangered species, threatens biodiversity and long-term availability**(Halder and Jha 2023).**

VII. FUTURE PERSPECTIVES

The future of plant-based drug discovery lies in integrating advanced technologies such as high-throughput screening, metabolomics, genomics, and nanotechnology-based drug delivery systems. Sustainable cultivation and conservation of medicinal plants, along with international collaborations, are crucial to harnessing their full potential. Furthermore, biotechnological approaches such as plant cell culture and genetic engineering may provide solutions for large-scale production of bioactive compounds.

VIII. CONCLUSION

Botanical resources represent a vast and underexplored reservoir of therapeutic agents. From morphine and quinine to paclitaxel and artemisinin, history demonstrates the indispensable role of plants in drug discovery. Their structural diversity, bioactivity, and ethnopharmacological background continue to inspire modern research. Overcoming challenges of variability, standardization, and sustainability through advanced technologies will be key to fully harnessing their potential. By integrating traditional knowledge with modern science, plant-derived compounds will remain central to the development of innovative medicines for the future.

REFERENCES

[1]. Dar, R. A., Shahnawaz, M., Ahanger, M. A., & Majid, I. U. (2023). Exploring the diverse bioactive compounds from medicinal plants: a review. J. Phytopharm, 12(3), 189-195.

[2]. Chaachouay, N., & Zidane, L. (2024). Plant-derived natural products: a source for drug discovery and development. Drugs and Drug Candidates, 3(1), 184-207.

[3]. Branch, S. K., &Agranat, I. (2014). "New drug" designations for new therapeutic entities: new active substance, new chemical entity, new biological entity, new molecular entity. Journal of medicinal chemistry, 57(21), 8729-8765.

[4]. Newman, D. J., & Cragg, G. M. (2020). Natural products as sources of new drugs over the nearly four decades from 01/1981 to 09/2019. Journal of natural products, 83(3), 770-803.

[5]. Harvey, A. L., Edrada-Ebel, R., & Quinn, R. J. (2015). The re-emergence of natural products for drug discovery in the genomics era. Nature reviews drug discovery, 14(2), 111-129.

[6]. Durand, G. A., Raoult, D., &Dubourg, G. (2019). Antibiotic discovery: history, methods and perspectives. International

journal of antimicrobial agents, 53(4), 371-382.
[7]. Tran, N., Pham, B., & Le, L. (2020). Bioactive compounds in anti-diabetic plants: From herbal medicine to modern drug discovery. Biology, 9(9), 252.
[8]. Upton, R., Graff, A., Jolliffe, G., Länger, R., & Williamson, E. (Eds.). (2016). American herbal pharmacopoeia: botanical pharmacognosy-microscopic characterization of botanical medicines. CRC press.
[9]. Kinghorn, A. D., & Kennelly, E. J. (2020). Medicinal applications of plant toxicants. In Handbook of plant and fungal toxicants (pp. 255-268). CRC Press.
[10]. Kayser, O. (2024). Quinine. In From the Maluku to Molecules: How Natural Substances Write History (pp. 269-296). Berlin, Heidelberg: Springer Berlin Heidelberg.
[11]. Manavi, M. A., Salehi, M., Mohammad Jafari, R., &Dehpour, A. R. (2024). From dyes to drugs: The historical impact and future potential of dyes in drug discovery. Archiv der Pharmazie, 357(11), e2400532.
[12]. Singh, M. (2017). Evaluating the therapeutic efficiency and drug targeting ability of alkaloids present in Rauwolfiaserpentina. International Journal of Green Pharmacy (IJGP), 11(03).
[13]. Weir, M. R. (2020). Reserpine: a new consideration of an old drug for refractory hypertension. American Journal of Hypertension, 33(8), 708-710.
[14]. Ghallab, Y. K., &Elassal, O. S. (2024). Biochemical and neuropharmacology of psychiatric disorders. In Nutrition and Psychiatric Disorders: An Evidence-Based Approach to Understanding the Diet-Brain Connection (pp. 25-47). Singapore: Springer Nature Singapore.
[15]. Schürrle, K. (2019). History, current state, and emerging applications of industrial biotechnology. Sustainability and Life Cycle Assessment in Industrial Biotechnology, 13-51.
[16]. Luisi, G. (2023). Antimalarial endoperoxides: from natural sesquiterpene drugs to a rising generation of synthetic congeners. Terpenes, 2, 158-227.
[17]. van der Pluijm, R. W., Amaratunga, C., Dhorda, M., &Dondorp, A. M. (2021). Triple artemisinin-based combination therapies for malaria–a new paradigm?. Trends in parasitology, 37(1), 15-24.
[18]. Sarkar, S. (2023). Role of paclitaxel and vinblastine in modern cancer therapy. Progress in Chemical and Biological Science [Internet]. Lincoln University College, Malaysia, 15-25.
[19]. Ejeta, B. M., Das, M. K., & Das, S. (2024). Recent Advances in Paclitaxel Drug Delivery: Challenges, Innovations, and Future Directions. Integrative Biomedical Research, 8(8), 1-13.
[20]. Khandelwal, R., Vagha, J. D., Meshram, R. J., Patel, A., & Khandelwal Jr, R. (2024). A comprehensive review on unveiling the journey of digoxin: past, present, and future perspectives. Cureus, 16(3).
[21]. Khandelwal, R., Vagha, J. D., Meshram, R. J., Patel, A., & Khandelwal Jr, R. (2024). A comprehensive review on unveiling the journey of digoxin: past, present, and future perspectives. Cureus, 16(3).
[22]. WhayneJr, T. F. (2018). Clinical use of digitalis: a state of the art review. American journal of cardiovascular drugs, 18(6), 427-440.
[23]. Hussain, G., Rasul, A., Anwar, H., Aziz, N., Razzaq, A., Wei, W., ...& Li, X. (2018). Role of plant derived alkaloids and their mechanism in neurodegenerative disorders. International journal of biological sciences, 14(3), 341.
[24]. Chihomvu, P., Ganesan, A., Gibbons, S., Woollard, K., & Hayes, M. A. (2024). Phytochemicals in drug discovery—A confluence of tradition and innovation. International journal of molecular sciences, 25(16), 8792.
[25]. Mony, T. J., Elahi, F., Choi, J. W., & Park, S. J. (2022). Neuropharmacological effects of terpenoids on preclinical animal models of psychiatric disorders: a review. Antioxidants, 11(9), 1834.
[26]. Ogbuagu, O. O., Mbata, A. O., Balogun, O. D., Oladapo, O., Ojo, O. O., &Muonde, M. (2022). Novel phytochemicals in traditional medicine: Isolation and pharmacological profiling of bioactive compounds. International Journal of Medical and All Body Health Research, 3(1), 63-71.

International Journal of Pharmaceutical Research and Applications
Volume 10, Issue 5 Sept - Oct 2025, pp: 633-640 www.ijprajournal.com ISSN: 2456-4494

[27]. Alara, O. R., Abdurahman, N. H., &Ukaegbu, C. I. (2021). Extraction of phenolic compounds: A review. Current research in food science, 4, 200-214.
[28]. Riaz, T., Akram, M., Laila, U., Zainab, R., Khalil, M. T., Iftikhar, M., ...& Parmar, P. (2023). Therapeutic applications of glycosides obtained from medicinal plants. International Archives of Integrated Medicine, 10(8).
[29]. Riaz, T., Akram, M., Laila, U., Zainab, R., Khalil, M. T., Iftikhar, M., ...& Parmar, P. (2023). Therapeutic applications of glycosides obtained from medicinal plants. International Archives of Integrated Medicine, 10(8).
[30]. Tiwari, P., Bajpai, M., & Sharma, A. (2023). Antimicrobials from medicinal plants: Key examples, success stories and prospects in tackling antibiotic resistance. Letters in Drug Design & Discovery, 20(4), 420-438.
[31]. Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018). Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians, 68(6), 394-424.
[32]. Bozkurt, B., Aguilar, D., Deswal, A., Dunbar, S. B., Francis, G. S., Horwich, T., ...& Yancy, C. (2016). Contributory risk and management of comorbidities of hypertension, obesity, diabetes mellitus, hyperlipidemia, and metabolic syndrome in chronic heart failure: a scientific statement from the American Heart Association. Circulation, 134(23), e535-e578.
[33]. Ayaz, M., Ullah, F., Sadiq, A., Kim, M. O., & Ali, T. (2019). Natural products-based drugs: potential therapeutics against Alzheimer's disease and other neurological disorders. Frontiers in pharmacology, 10, 1417.
[34]. Sharma, N. (2014). Free radicals, antioxidants and disease. Biology and Medicine, 6(3), 1.
[35]. Aryal, B., Raut, B. K., Bhattarai, S., Bhandari, S., Tandan, P., Gyawali, K., ...&Parajuli, N. (2022). Potential therapeutic applications of plant-derived alkaloids against inflammatory and neurodegenerative diseases. Evidence-Based Complementary and Alternative Medicine, 2022(1), 7299778.
[36]. Daley, S. K., & Cordell, G. A. (2021). Alkaloids in contemporary drug discovery to meet global disease needs. Molecules, 26(13), 3800.
[37]. Pushpangadan, P., George, V., Ijinu, T. P., &Chithra, M. A. (2018). Biodiversity, bioprospecting, traditional knowledge. Sustainable development and value added products: a review. Journal of Traditional Medicine & Clinical Naturopathy, 7(01), 1-7.
[38]. Shukla, S. S., Pandey, R. K., Gidwani, B., & Kalyani, G. (2023). Approach for Herbal Standardization. In Pharmaceutical Calibration, Validation and Qualification: A Comprehensive Approach (pp. 187-198). Singapore: Springer Nature Singapore.
[39]. Halder, M., & Jha, S. (2023). The current status of population extinction and biodiversity crisis of medicinal plants. In Medicinal Plants: Biodiversity, Biotechnology and Conservation (pp. 3-38). Singapore: Springer Nature Singapore.